Kong Hao, Liu Yancheng, Luo Sai, Li Qiaoqiao, Wang Qinglu
Key Laboratory of Biomedical Engineering & Technology of Shandong High School, Qilu Medical University, China.
Intern Med. 2016;55(15):1977-84. doi: 10.2169/internalmedicine.55.6214. Epub 2016 Aug 1.
Objective As the calreticulin (CALR) mutation frequency is significantly associated with essential thrombocythemia (ET) and primary myelofibrosis (PMF), this mutation may be an important biomarker in patients with ET and PMF. Methods We performed a literature search until April 2015 and obtained 21 relevant studies. The outcome was pooled as the effect size by using the Stata software program. Results The CALR mutation frequencies in patients with ET and PMF were 19% and 22%, respectively. The CALR mutation ratio in Asian patients with ET was 23% and higher than that in European-American patients (16%). Moreover, the mutation ratio in Asian patients with PMF was lower (21%) than that in European-American patients (23%). A slight trend toward fibrotic transformation was found in ET with CALR mutations, whereas leukemic transformation was not significant in patients with ET or PMF with CALR mutations. Conclusion CALR mutations significantly influence the incident of ET as demonstrated by the meta-analysis.
目的 鉴于钙网蛋白(CALR)突变频率与原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)显著相关,该突变可能是ET和PMF患者的重要生物标志物。方法 我们进行了文献检索,截至2015年4月,共获得21项相关研究。使用Stata软件程序将结果汇总为效应量。结果 ET和PMF患者的CALR突变频率分别为19%和22%。亚洲ET患者的CALR突变率为23%,高于欧美患者(16%)。此外,亚洲PMF患者的突变率(21%)低于欧美患者(23%)。在伴有CALR突变的ET患者中发现有轻微的纤维化转化趋势,而在伴有CALR突变的ET或PMF患者中白血病转化不明显。结论 荟萃分析表明,CALR突变显著影响ET的发病情况。